Physician profile

Steve Springer

Family Medicine · Lake Charles, LA

NPI 1477538619

$6,254.47

in general payments reported to CMS, 2019-2025

38 companies · $865 in 2025

The $865 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$2,765.39

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Astrazeneca Pharmaceuticals Lp $971.71 2019-2025 Farxiga, Airsupra, Breztri
Abbvie INC. $686.65 2021-2025 Vraylar, Ubrelvy, Botox
Lilly USA, LLC $608.52 2019-2025 Mounjaro, Jardiance, Zepbound
Novo Nordisk INC $451.44 2019-2025 Ozempic, Rybelsus
Glaxosmithkline, LLC. $435.83 2019-2025 Trelegy Ellipta, Arexvy, Shingrix
Boehringer Ingelheim Pharmaceuticals, INC. $392.56 2019-2025 Jardiance, Synjardy
Dexcom, INC. $258.75 2019-2025 Dexcom G6 Transmitter
Novartis Pharmaceuticals Corporation $245.18 2021-2025
Abbott Laboratories $242.74 2021-2025 Freestyle Libre 3
Pfizer INC. $205.86 2019-2025
Phathom Pharmaceuticals, INC. $177.55 2023-2025 Voquezna
Exact Sciences Corporation $173.59 2023-2025 Cologuard Collection Kit, The Cologuard Plus Collection Kit
Takeda Pharmaceuticals U.S.A., INC. $132.72 2019-2022
Bayer Healthcare Pharmaceuticals INC. $130.47 2021-2025
Sanofi-Aventis U.S. LLC $126.41 2019-2021
Show all 38 companies
CompanyGeneral paymentsYearsTop products
Esperion Therapeutics, INC. $123.69 2020-2021
Merck Sharp & Dohme LLC $112.76 2019-2021
Globus Medical, INC. $106.68 2021
Daiichi Sankyo INC. $77.11 2019-2022
Smith+Nephew, INC. $69.14 2023-2025 Grafix, Stravix, Stravix Pl
Musculoskeletal Transplant Foundation INC. $63.93 2020-2021
Astellas Pharma US INC $59.20 2023-2024 Veozah, Myrbetriq
Allergan, INC. $57.71 2019-2020
Amgen INC. $53.05 2020-2025 Repatha, Otezla, Repatha
Noven Therapeutics, LLC $47.00 2024 Xelstrym
Amarin Pharma, INC. $34.28 2021
Teva Pharmaceuticals USA, INC. $27.57 2019-2020
Otsuka America Pharmaceutical, INC. $24.74 2025 Rexulti
Currax Pharmaceuticals LLC $21.44 2022
Organogenesis INC. $19.56 2020
Idorsia Pharmaceuticals US INC $17.12 2023 Quviviq
Shire North American Group INC $16.55 2019
Shionogi INC $14.90 2019
Janssen Pharmaceuticals, INC $14.34 2020
Supernus Pharmaceuticals, INC. $14.24 2023 Qelbree
Adlon Therapeutics L.P. $13.82 2020
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $13.40 2019
Amneal Pharmaceuticals LLC $12.26 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Steve Springer

$6,254.47

in general payments reported 2019-2025

Years
2019-2025
Top company
Astrazeneca Pharmaceuticals Lp
Context
The $865 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).

https://glasscript.com/doctor/339462/steve-springer

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.